News & Reports

Evonik Industries


Here you can find "Investor Relations News" with the latest news from our company and the Ad-hoc announcements.

Ad-hoc announcements

Issuers of financial instruments issued in the European Union are required to publish as soon as possible information which has not been made public, which directly affects the issuer and which could have a significant effect on the prices of such financial instruments (Article 17 of the European Market Abuse Regulation - "Marktmissbrauchsverordnung"). Such information is published by issuing so-called ad-hoc announcements.. You can access the Ad-hoc announcements here.

Further information

Investor Relations News

, Investors

Evonik is streamlining processes and reducing administrative and selling expenses

• Next step towards a performance-oriented corporate culture with a healthy cost structure
• Up to 1,000 jobs to be cut worldwide in administration and sales by year-end 2020
• Agreement with employee representatives on key points

, Investors

Evonik made a good start to 2018

• Adjusted EBITDA rises 14 percent to €679 million
• Sales increase 1 percent to €3.68 billion
• Full-year forecast confirmed

, Investors

Evonik invests in American skin technology start-up mySkin

• Evonik is driving digitalization in the cosmetic industry
• mySkin’s unique handheld device “OKU” measures a variety of skin properties and recommends care products
• Breakthrough in how consumers can measure and improve their skin

, Investors

Evonik to close its Kaba site in Hungary

Essen (Germany) / Kaba (Hungary). Evonik will stop its amino acid production at its Hungarian Kaba site by the end of April 2018. There Evonik Agroferm Zrt., a subsidiary of Evonik, currently employs about 120 people.

, Investors

Evonik plans new polyamide 12 complex in Marl

• Evonik's largest investment in Germany
• Targeted strengthening of the Resource Efficiency growth segment
• Strong growth for high-performance polymer polyamide 12 in the automotive sector, the oil and gas industry, and 3D printing

, Investors

A good performance in 2017

• Forecast fully achieved: Adjusted EBITDA of €2.36 billion is at the upper end of the range
• Outlook for 2018: Sales and earnings growth,
adjusted EBITDA between €2.4 billion and €2.6 billion
• Active portfolio management: Examining strategic options for the methacrylates business